Discussion  by unknown
timing of activation may prove to be an important therapeu-
tic intervention in attenuating the robust inflammatory re-
sponse after lung transplantation.
In conclusion, this report demonstrates that pretreatment
with an A2AR agonist protects the lung against IR injury and
that further improvements in oxygenation and lung compli-
ance occur with concurrent A2AR activation during reper-
fusion. The ability to exploit and further characterize innate
physiologic mechanisms of protection that minimize the
contribution of inflammatory cells will likely prove to be
critical in reducing the destructive consequences of LIRI
and ultimately improve the care of patients with end-stage
lung disease.
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Discussion
Dr Mark J. Krasna (Towson, Md). What is the anti-inflammatory
effect that you think ATL-313 has? Tell us what your view is.
Dr Gazoni. A2AR agonists significantly decrease the amount of
leukocyte activation and decrease the interaction of neutrophils,
for example, with endothelial cells. One of the mechanisms behind
that is decreasing the expression of adhesion molecules such as
intercellular adhesion molecule and P-selectin. These are some of
the few widely documented anti-inflammatory effects of the A2AR
agonists.
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Dr Frank W. Sellke (Boston, Mass). I have a technical ques-
tion. You subjected the lungs to 18 hours of ischemia and then
reperfusion. Did you reperfuse with blood or with a crystalloid
solution?
Dr Gazoni. We reperfused with whole blood. After working on
this model for 2 years, I do not think I can handle seeing another
rabbit. We actually have to exsanguinate 2 rabbits to reperfuse the
harvested lung. So for every lung that we get data from there are
actually 3 rabbits that are put to death total.
Dr Sellke. That was my next question. Did you kill the rabbits
right before you were going to reperfuse the lungs or did you kill
them at the same time and freeze the blood?
Dr Gazoni. As I am priming the reperfusion apparatus, I
actually administer anesthesia to the blood donors with a combi-
nation of ketamine, xylazine, and vecuronium. As I open up the
chest, the heart is still beating and I then cannulate the right
atrium/ventricle. The blood then goes directly to the reperfusion
apparatus.
Dr Sellke. One other question has to do with statistics. Did you
do a multiple comparison test, or how did you compare the
different groups? If you have 6 groups you have to have tremen-
dous differences to reach statistical significance.
Dr Gazoni. We performed an ANOVA initially to see that
there are actual differences between all groups throughout all time
periods. All ANOVA tests were significant. The Tukey honest
significant difference multiple-comparison test was then used to
determine which groups were significantly different.
Dr David H. Harpole (Durham, NC). This is a very elegant
technique. The only question I have is very simple. I read the paper
and read this, and I could not exactly see. You had standard
deviations. How many animals were in each group?
Dr Gazoni. Six. This is the third experiment I have performed
with this model. I have probably harvested and reperfused about
400 lungs. By the time I did this experiment, which is the last
experiment I have done with this model, I have gotten the tech-
nique down fairly well.
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